(2025) have investigated a novel treatment strategy for mantle cell lymphoma that involves inhibiting two proteins, BIRC5 and MCL-1.
This method aims to address the issue of drug resistance, which often complicates treatment effectiveness.
Drug resistance occurs when cancer cells adapt and become less responsive to therapies, making management more challenging.
The findings indicate that by targeting these specific proteins linked to cancer cell survival, treatment outcomes could be enhanced.
Researchers believe that focusing on BIRC5 and MCL-1 may lead to the development of more effective therapies for patients who have become resistant to current treatments.
This approach has the potential to result in longer remission periods and improved overall survival rates for individuals affected by mantle cell lymphoma.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
